Correlation Between Kymera Therapeutics and Foghorn Therapeutics

Can any of the company-specific risk be diversified away by investing in both Kymera Therapeutics and Foghorn Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Kymera Therapeutics and Foghorn Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Kymera Therapeutics and Foghorn Therapeutics, you can compare the effects of market volatilities on Kymera Therapeutics and Foghorn Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kymera Therapeutics with a short position of Foghorn Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kymera Therapeutics and Foghorn Therapeutics.

Diversification Opportunities for Kymera Therapeutics and Foghorn Therapeutics

0.03

Correlation Coefficient

Kymera Therapeutics  Foghorn Therapeutics

Significant diversification

The 3 months correlation between Kymera and Foghorn is 0.03. Overlapping area represents the amount of risk that can be diversified away by holding Kymera Therapeutics and Foghorn Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Foghorn Therapeutics and Kymera Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kymera Therapeutics are associated (or correlated) with Foghorn Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Foghorn Therapeutics has no effect on the direction of Kymera Therapeutics i.e., Kymera Therapeutics and Foghorn Therapeutics go up and down completely randomly.

Pair Corralation between Kymera Therapeutics and Foghorn Therapeutics

Given the investment horizon of 90 days Kymera Therapeutics is expected to under-perform the Foghorn Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Kymera Therapeutics is 1.27 times less risky than Foghorn Therapeutics. The stock trades about -0.09 of its potential returns per unit of risk. The Foghorn Therapeutics is currently generating about -0.03 of returns per unit of risk over similar time horizon. If you would invest  461.00  in Foghorn Therapeutics on December 29, 2024 and sell it today you would lose (73.00) from holding Foghorn Therapeutics or give up 15.84% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Kymera Therapeutics  vs.  Foghorn Therapeutics

Kymera Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Kymera Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's primary indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Foghorn Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Foghorn Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Pair Trading with Kymera Therapeutics and Foghorn Therapeutics

The main advantage of trading using opposite Kymera Therapeutics and Foghorn Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kymera Therapeutics position performs unexpectedly, Foghorn Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Foghorn Therapeutics will offset losses from the drop in Foghorn Therapeutics' long position.

The idea behind Kymera Therapeutics and Foghorn Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.